# Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

> **NCT06574126** · PHASE2 · RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 20 (estimated)

## Conditions studied

- High Risk Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
- **DRUG:** Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion

## Key facts

- **NCT ID:** NCT06574126
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2032-09-30
- **Final completion:** 2032-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574126, "Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06574126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*